The strong beat and guidance raise confirm accelerating operational momentum and deleveraging. With 89% analyst bullishness and a 100% historical win rate on prior BVS calls, the stock is likely to re-rate higher. Watch for continued debt paydown and potential upside to revenue guidance if growth trends persist.
Price Chart
Executive Summary
Bioventus reported Q1 2026 revenue of $132.1M (+7% YoY) and GAAP EPS of $0.04, swinging from a -$0.04 loss in the prior year. Non-GAAP EPS of $0.15 beat the $0.07 consensus by 114%, driven by revenue growth, margin expansion, and lower interest expense. The company raised full-year 2026 adjusted EPS guidance to $0.75-$0.79 and cash from operations guidance to $84M-$89M, while reaffirming revenue guidance of $600M-$610M.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $132.1M, +7% YoY, above $129.9M consensus
- GAAP EPS $0.04 vs -$0.04 YoY; Non-GAAP EPS $0.15 vs $0.08 YoY
- Non-GAAP EPS of $0.15 beat consensus estimate of $0.07 by 114%
- Adjusted EBITDA $23.9M, +24% YoY; operating cash flow $8.9M vs -$19.3M YoY
- Raised FY2026 adjusted EPS guidance to $0.75-$0.79 (from $0.73-$0.77) and cash from operations to $84M-$89M (from $82M-$87M)
- Reaffirmed FY2026 revenue guidance of $600M-$610M (+6-7% growth)
- Made $22M discretionary principal prepayment on term loan in March 2026
- Pain Treatments revenue +7.7%, Surgical Solutions +6.2%, Restorative Therapies +4.6%
Financial Impact
Q1 revenue beat by $2.2M vs consensus; Non-GAAP EPS beat by $0.08 vs consensus; raised FY guidance by $0.02 on EPS and $2M on cash from operations
Risk Factors
- Revenue guidance unchanged despite Q1 beat — implies deceleration in remaining quarters
- One-time $4.2M favorable rebate benefit in Pain Treatments may not repeat
- Debt still elevated at $272M despite $22M prepayment; interest expense remains a drag
- Tariff and regulatory risks cited in forward-looking statements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288701 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 6w ago | Institutional Cluster | $13.88 $13.16 | ▼ −5.19% | ▼ −3.66% | $13.13 (−5.40%) |
Aug 5, 2026 8w ago | 8-K | $15.26 $14.37 | ▼ −5.83% | ▼ −5.23% | $13.13 (−13.96%) |
Aug 5, 2026 8w ago | Press Release | $15.26 $14.37 | ▼ −5.83% | ▼ −5.23% | $13.13 (−13.96%) |
Jun 11, 2026 16w ago | Institutional Cluster | $8.68 $12.22 | ▼ −40.78% | ▼ −38.89% | $13.13 (−51.27%) |
Jun 2, 2026 17w ago | Press Release | $8.11 $9.85 | ▼ −21.45% | ▼ −23.02% | $13.13 (−61.90%) |
May 21, 2026 19w ago | 8-K | $9.28 $8.99 | ▼ −3.13% | ▼ −1.71% | $13.13 (+41.49%) |
May 8, 2026 21w ago | Court Ruling | $10.50 $9.04 | ▼ −13.90% | ▼ −13.93% | $13.13 (+25.05%) |
May 6, 2026 21w ago | 8-K | $10.92 $8.55 | ▼ −21.70% | ▼ −24.48% | $13.13 (+20.24%) |
May 6, 2026 21w ago | Press Release | $10.92 $8.55 | ▼ −21.70% | ▼ −24.48% | $13.13 (+20.24%) |
Apr 28, 2026 22w ago | Press Release | $9.67 $8.87 | ▼ −8.27% | ▼ −14.32% | $13.13 (+35.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access